newsfilter
← Latest News
GlobeNewswire·

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

• First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 • Cadisegliatin intellectual property portfolio